You are here

DNA Aptamers for Passive Immunity Against Bunyaviruses

Award Information
Agency: Department of Defense
Branch: Office for Chemical and Biological Defense
Contract: W911SR-22-P-0007
Agency Tracking Number: C212-006-0068
Amount: $167,482.92
Phase: Phase I
Program: SBIR
Solicitation Topic Code: CBD212-006
Solicitation Number: 21.2
Timeline
Solicitation Year: 2021
Award Year: 2022
Award Start Date (Proposal Award Date): 2022-03-18
Award End Date (Contract End Date): 2022-08-31
Small Business Information
6201 East Oltorf St. Suite 400
Austin, TX 78741-1111
United States
DUNS: 100651798
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 John Bruno
 (512) 389-9990
 jbruno@nanohmics.com
Business Contact
 Michael Mayo
Phone: (512) 389-9990
Email: mmayo@nanohmics.com
Research Institution
N/A
Abstract

Aptamers are oligonucleotides that bind like antibodies to envelope and other viral proteins to block or inhibit viral host cell entry and replication for passive immunity until a patient can mount an effective immune response. In Phase I, Nanohmics proposes to test existing DNA aptamers against Crimean Congo Hemorrhagic Fever envelope epitopes funded by a previous SBIR Phase II contract W81XWH-09-C-0029 and published by the P.I. (BMC Research Notes 5:633, 2012) in tissue culture plaque inhibition assays at the BSL-4 laboratories of the Texas Biomedical Research Institute (TBRI) in nearby San Antonio, TX. The extant CCHF aptamers will also be tested against other Bunyaviruses for plaque inhibition to determine the breadth of efficacy. In Phase II, the CCHF aptamers will be tested in animal models and new aptamers against other Bunyaviruses will be developed and tested as oral formulations in chitin nanoparticles and injectable aptamer-3’-PEG or –Fc conjugates for extended pharmacokinetics in vivo. Nanohmics will also characterize aptamer binding to each viral epitope with 3D computer docking models developed and published by the P.I. (Bruno, J. Molec. Recognition Aug 16:e2809, 2019) to further improve binding, if necessary, by targeted insertion of exotic bases or chemical adducts in the aptamers.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government